Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma

BACKGROUND: Antibodies targeting the programmed cell death-1 (PD-1)/PD-ligand 1 (PD-1/PD-L1) checkpoint have shown promising clinical activity in patients with advanced urothelial carcinoma (UC). Expression of PD-L1 in UC tumors has been investigated using different antibody clones, staining protoco...

Descripción completa

Detalles Bibliográficos
Autores principales: Zajac, Magdalena, Scott, Marietta, Ratcliffe, Marianne, Scorer, Paul, Barker, Craig, Al-Masri, Hytham, Rebelatto, Marlon C., Walker, Jill
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720992/
https://www.ncbi.nlm.nih.gov/pubmed/31477145
http://dx.doi.org/10.1186/s13000-019-0873-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6720992/
https://www.ncbi.nlm.nih.gov/pubmed/31477145
http://dx.doi.org/10.1186/s13000-019-0873-6

Ejemplares similares